CRVS Earnings & Financial Statements
Corvus Pharmaceuticals, Inc.
$9.86
+$0.48(+5.12%)
32
Overall
40
Value
18
Tech
39
Quality
Market Cap
$789.05M
Volume
395.30K
52W Range
$6.39 - $26.95
Target Price
$33.14
CRVS earnings and financial statements: Corvus Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
CRVS Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating income | -$42.97M | -$27.55M | -$23.41M | -$32.56M | -$38.63M |
| EBITDA | -$15.18M | -$62.21M | -$26.88M | -$40.94M | -$38.17M |
| Net income | -$15.28M | -$62.29M | -$27.03M | -$41.31M | -$43.24M |
| EPS (diluted) | $-0.53 | $-1.02 | $-0.56 | $-0.89 | $-1.03 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $71.12M | $68.91M | $45.55M | $68.24M | $109.45M |
| Total liabilities | $9.91M | $36.34M | $6.87M | $12.13M | $12.29M |
| Shareholders’ equity | $61.20M | $32.57M | $38.68M | $56.12M | $97.16M |
| Cash and equivalents | $4.58M | $8.74M | $12.62M | $13.16M | $63.46M |
| Long-term debt | $534.0K | $937.0K | - | $1.37M | $2.60M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$32.80M | -$25.42M | -$23.93M | -$27.02M | -$36.72M |
| Capital expenditure | -$174.0K | $5.0K | -$34.0K | -$269.0K | -$5.0K |
| Free cash flow | -$32.97M | -$25.42M | -$23.97M | -$27.29M | -$36.72M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CRVS | $9.86 | +5.1% | 395.30K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Corvus Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW